October 15, 2026

Acorda Therapeutics, Inc., Petitioner v. Alkermes PLC

Track this case

Case Number:

26-498

Court:

Supreme Court

Nature of Suit:

Firms

Companies

Sectors & Industries:

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. November 09, 2026

    Justices Pass On Reviewing MS Drug Arbitration Feud

    The U.S. Supreme Court on Monday passed on reviewing a Second Circuit decision refusing to add some $66 million to a $16.6 million arbitral award issued to Acorda Therapeutics in a multiple sclerosis drug dispute, a petition that sought clarity on when an arbitrator "manifestly disregards" the law.

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login